Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations.

"CONFLICT OF INTEREST STATEMENT The authors have no financial or non-financial potential conflicts of interest to declare related to this project. M.C.M. is partially supported through a Vasculitis Clinical Research Consortium-Vasculitis Foundation Fellowship. P.G. received honoraria for consulting from CSLVifor. H.-J.A. received honoraria or lecture fees from AstraZeneca, Bayer, Eleva, GlaxoSmithKline, Kezar, Eli Lilly, Novartis, Otsuka, Previpharma and Vifor. A.B. has received honoraria or consulting fees from AstraZeneca, Bayer, ChemoCentryx, Merck/MSD and Vifor. D.Geetha received consulting fees from ChemoCentryx and Aurinia. F.C.F. received unrestricted research funding from Genentech/Roche. D.R.W.J. received honoraria or consulting fees from Amgen, AstraZeneca, Aurinia, Bristol-Myers Squibb, Boehringer Ingelheim, Chemocentryx, GlaxoSmithKline, National Institute for Health and Care Excellence, Novartis, Otsuka, Roche/Genentech, Takeda, UCB and Vifor. K.I.S. has received honoraria from Bayer Pharmaceuticals. A.K. received honoraria for consulting from Walden Biosciences, Catalyst Biosciences, Otsuka, UriSalt, Vifor Pharma and Delta 4, and speaking fees from Vifor Pharma and Otsuka."

"FUNDING This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors."